SHR-1707 placebo

DRUG2 trials

Sponsors

Shanghai Hengrui Pharmaceutical Co., Ltd.

Conditions

Alzheimer's Disease

Phase 1

A Study of SHR-1707 With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

CompletedNCT05681819

Shanghai Hengrui Pharmaceutical Co., Ltd.Alzheimer's Disease

Start: 2023-02-17End: 2025-08-13Updated: 2026-05-05

Phase 2

Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients

TerminatedNCT06199037

Shanghai Hengrui Pharmaceutical Co., Ltd.Alzheimer's Disease

Start: 2024-02-05End: 2026-01-30Updated: 2026-05-13

Related Papers

A randomized, double‐blind, placebo‐controlled phase 2 study of SHR‐1707, an anti‐amyloid‐β antibody, in patients with mild cognitive impairment and mild Alzheimer's disease

Alzheimer s & Dementia2025-12-01

Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR-1707 in healthy adult subjects: two randomized, double-blind, single-ascending-dose, phase 1 studies.

2024-10-105 citations

A randomized, double‐blind, placebo‐controlled phase 1b study to evaluate the safety, tolerability, and pharmacodynamics of an anti‐amyloid‐β antibody SHR‐1707 in patients with mild cognitive impairment and mild Alzheimer’s disease

Alzheimer s & Dementia2023-12-01